Loading stock data…
Faeth Therapeutics, Inc. (FTH)
$39.20-0.85 (-2.12%)
Market ClosedLast close Sep 8
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Faeth Therapeutics, Inc. in the Healthcare sector is trading at $39.20 with a market capitalization of $836M. Wall Street consensus targets $54.64 (11 analysts), implying a +39.4% move over the next 12 months. The stock is currently near its 52-week high of $42.14, remaining 79.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +39.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$170.63M↓ | -$4.96M↓ | -$4.85M↑ | -$5.21M↑ | -$7.27M |
| Net Income | -$170.24M↓ | -$4.72M↓ | -$4.57M↑ | -$4.94M↑ | -$6.86M |
Peer Comparison
JNJUNHPFE
Fundamentals
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in develop...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$835.68M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
134.36%
Volume
Today's trading volume
292,077
Recent News
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know
The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls
Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls
Frontier Transport Holdings (JSE:FTH) Will Pay A Dividend Of ZAR0.277
The board of Frontier Transport Holdings Limited ( JSE:FTH ) has announced that it will pay a dividend of ZAR0.277 per...
Frontier Transport Holdings (JSE:FTH) Might Become A Compounding Machine
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...